Clinical Trial News and Research

RSS

AVEO receives EMA orphan medicinal product designation for tivozanib

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received orphan medicinal product designation for tivozanib (N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate), its oral, triple VEGF receptor inhibitor, for the treatment of renal cell carcinoma by the European Medicines Agency (EMA).

24 Jun 2010

IDEV enters exclusive distribution agreement with TriReme for GliderXtreme PTA balloon catheter

IDEV Technologies, Incorporated (IDEV), an emerging leader in the development and marketing of minimally invasive medical technologies, today announced that it has entered into an exclusive distribution agreement covering the U.S. and Germany for TriReme Medical, Inc.'s (TriReme) GliderXtreme™ PTA balloon catheter, an advanced product with specific features for the expanding Peripheral Arterial Disease (PAD) market.

24 Jun 2010

UCSD School of Medicine receives $5.3M grant to study effect of weight loss in breast cancer survivors

The University of California, San Diego School of Medicine has received a $5.3 million grant from the National Cancer Institute to conduct and lead a first-of-its-kind, four-year clinical trial to show the effects of weight loss and increased physical activity on quality of life and on co-existing medical conditions in overweight breast cancer survivors.

24 Jun 2010

Spherix to explore triglycerides for D-tagatose therapy

Spherix Incorporated, an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it will explore triglycerides as a potential therapeutic opportunity for its D-tagatose therapy, pending a review of data from a Phase 3 clinical trial the Company is conducting on the use of D-tagatose as a treatment for Type 2 diabetes.

24 Jun 2010

Advaxis completes enrollment of vanguard patient group in phase II clinical trial for cervical intraepithelial neoplasia

Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia.

24 Jun 2010

Tikcro Technologies reports net income of $1.9 million for first-quarter 2010

Tikcro Technologies Ltd. today reported results for the first quarter ended March 31, 2010.

24 Jun 2010

SIGA completes fourth human clinical trial of ST-246 smallpox antiviral drug candidate

SIGA Technologies, Inc., a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced today the successful completion of its fourth human clinical trial, supporting the safety and tolerability of the anticipated clinical dose of ST-246®, SIGA's lead smallpox antiviral drug candidate.

23 Jun 2010

$Phase 1 clinical trial of XMT-1107 initiated in patients with refractory advanced solid tumors$

Phase 1 clinical trial of XMT-1107 initiated in patients with refractory advanced solid tumors

Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana's Fleximer platform. Mersana's XMT-1001, a conjugate of Fleximer and camptothecin, is currently completing a Phase 1 study.

23 Jun 2010

MAP Pharmaceuticals to present new analyses on LEVADEX from FREEDOM-301 Phase 3 clinical trial

MAP Pharmaceuticals, Inc. announced today it will present new analyses from the FREEDOM-301 Phase 3 clinical trial in a late breaker session at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California on Friday, June 25 from 3:30 to 4:00 pm PT. The presentation will show that the Company's investigational LEVADEX™ orally inhaled migraine therapy was effective irrespective of when it was administered during a migraine cycle.

23 Jun 2010

New presentations on neuroendocrine tumors at ESMO 12th World Congress on Gastrointestinal Cancer

Groundbreaking studies will be presented at the ESMO 12th World Congress on Gastrointestinal Cancer next week in Barcelona, Spain, including exciting new data on treatment for neuroendocrine tumors. "The presentations this year are very significant for clinicians, and outline real progress in the development of agents that are effective in managing and treating gastrointestinal diseases," says Eric Van Cutsem, MD, PhD of the University Hospital Gasthuisberg in Leuven, Belgium and Congress co-chair.

23 Jun 2010

Corgenix receives new European patent for AtherOx technology

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, announced today the issuance of one new European patent for the company's AtherOx® (oxLDL/B2GPI) technology and the publication of an important clinical trial studying oxLDL/B2GPI levels in patients with acute coronary syndrome (ACS).

23 Jun 2010

UAB receives $1.47M NHLBI grant to study red blood cell lesion

Researchers in the University of Alabama at Birmingham (UAB) departments of Pathology, Microbiology and Surgery have received a $1.47 million grant from the National Heart, Lung, and Blood Institute (NHLBI) to study so-called red blood cell lesion, a term given to the potentially harmful changes in red blood cells that have been stored for longer times after collection.

23 Jun 2010

Researchers identify promising gene therapy for DMD

CureDuchenne, the Orange County non-profit focused on finding a cure for Duchenne muscular dystrophy (DMD) is one step closer to that goal through the work of Dr. Jeff Chamberlain.

23 Jun 2010

MJFF supports Ceregene's CERE-120 Phase 2 study for PD with $2.5M award

The Michael J. Fox Foundation for Parkinson's Research (MJFF) will provide $2.5 million to support Ceregene Inc.'s new Phase 2 study of CERE-120. This novel gene therapy product delivers the gene for neurturin, a potent neurotrophic (growth) factor that has shown potential to improve the status of degenerating neurons in both preclinical and clinical studies. CERE-120 has the potential to improve motor function as well as slow Parkinson's disease (PD) progression.

23 Jun 2010

Phase I/II clinical trials show crizotinib reduces lung cancer tumors

Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.

23 Jun 2010

Biovest targets mantle cell lymphoma as next indication for BiovaxID

Biovest International, Inc. (Other OTC:BVTI) today announced at the Active Immunotherapeutics Forum in Barcelona, Spain, that the Company is targeting mantle cell lymphoma, in addition to follicular lymphoma, as a next indication for its personalized cancer vaccine, BiovaxID. At the conference, the Company reviewed positive data from an open label Phase II mantle cell lymphoma clinical trial and reported plans to meet with the FDA later this year to discuss a pathway to seek regulatory approval for this hematological indication for which there is no current consensus standard-of-care.

22 Jun 2010

Protea Biosciences, Mayoly-Spindler commence Phase I/IIA human clinical trial for new recombinant Lipase

Protea Biosciences, Inc., a leading developer of new technology for pharmaceutical research, announced today that the company, in partnership with Mayoly-Spindler, a European pharmaceutical company, has commenced a Phase I/IIA human clinical trial for a new recombinant Lipase.

22 Jun 2010

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled "Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques." The paper, co-authored by researchers from Merck, University of Pennsylvania School of Medicine, and Inovio Pharmaceuticals, notes that significant advances in the design, formulation, and delivery of DNA plasmid-based vaccines have dramatically increased their ability to induce antigen-specific immune responses.

22 Jun 2010

Antibody treatment could significantly improve lives following spinal cord injury: Researchers

The United States Department of Defense Spinal Cord Injury Research Program has announced a grant of more than a million dollars U.S. to support research at the Robarts Research Institute at The University of Western Ontario (Western). The spinal cord injury research team of Gregory Dekaban, Arthur Brown, Lynne Weaver and Paula Foster, in collaboration with Brian Kwon of the University of British Columbia and Kyle Petersen of the U.S. Naval Medical Research Center, is working on a new therapy designed to limit the damage caused by inflammation immediately following spinal cord injury.

22 Jun 2010

Gastric cancer drug market to grow from $700M in 2009 to $1.5B in 2019

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rapid uptake and market penetration of key targeted agents, beginning with Roche/Genentech/Chugai's Herceptin, will drive the gastric cancer drug market to more than double, from $700 million in 2009 to nearly $1.5 billion in 2019.

22 Jun 2010

Clinical Trial News and Research

AVEO receives EMA orphan medicinal product designation for tivozanib

IDEV enters exclusive distribution agreement with TriReme for GliderXtreme PTA balloon catheter

UCSD School of Medicine receives $5.3M grant to study effect of weight loss in breast cancer survivors

Spherix to explore triglycerides for D-tagatose therapy

Advaxis completes enrollment of vanguard patient group in phase II clinical trial for cervical intraepithelial neoplasia

Tikcro Technologies reports net income of $1.9 million for first-quarter 2010

SIGA completes fourth human clinical trial of ST-246 smallpox antiviral drug candidate

Phase 1 clinical trial of XMT-1107 initiated in patients with refractory advanced solid tumors

MAP Pharmaceuticals to present new analyses on LEVADEX from FREEDOM-301 Phase 3 clinical trial

New presentations on neuroendocrine tumors at ESMO 12th World Congress on Gastrointestinal Cancer

Corgenix receives new European patent for AtherOx technology

UAB receives $1.47M NHLBI grant to study red blood cell lesion

Researchers identify promising gene therapy for DMD

MJFF supports Ceregene's CERE-120 Phase 2 study for PD with $2.5M award

Phase I/II clinical trials show crizotinib reduces lung cancer tumors

Biovest targets mantle cell lymphoma as next indication for BiovaxID

Protea Biosciences, Mayoly-Spindler commence Phase I/IIA human clinical trial for new recombinant Lipase

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

Antibody treatment could significantly improve lives following spinal cord injury: Researchers

Gastric cancer drug market to grow from $700M in 2009 to $1.5B in 2019

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News